Physician profile
Christopher T Oswald
NPI 1346236403
$719.65
in general payments reported to CMS, 2019-2025
15 companies · $71.90 in 2025
The $71.90 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.95 · 2021: $29.76 · 2022: $83.61 · 2023: $164 · 2024: $297 · 2025: $71.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $186.01 | 2024 | Impella |
| Pfizer INC. | $86.78 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $82.37 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.93 | 2022-2024 | Jardiance |
| Boston Scientific Corporation | $54.76 | 2019-2024 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.14 | 2019-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $30.39 | 2023-2024 | Brilinta |
| Abbott Laboratories | $29.42 | 2019-2023 | Jot Dx |
| Biotronik INC. | $27.88 | 2022 | |
| Scpharmaceuticals INC. | $26.07 | 2025 | |
| Amgen INC. | $19.75 | 2025 | Repatha |
| Lantheus Medical Imaging, INC. | $16.06 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.41 | 2024 | Camzyos |
| Medtronic Vascular, INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Oswald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.